


---

**From:** Al Paonessa III <al.paonessa3@andanet.com>  
**Sent:** Friday, July 24, 2009 3:32 PM  
**To:** Michael Cochrane; Patrick Cochrane  
**Subject:** Re: Approval

Yes, but let's set up a quarterly review sop for these type of accounts. Something to document each quarter.

 Michael Cochrane

----- Original Message -----

**From:** Michael Cochrane  
**Sent:** 07/24/2009 11:19 AM EDT  
**To:** Al Paonessa III; Patrick Cochrane  
**Subject:** Fw: Approval

This account needs another increase. Month to date they are 87% non controlled units. In 7 months this year they have doubled their business with us over all of last year. They are at 2.1 mil year to date. Can we make the unlimited like BJK? They are at 500,000 now. Their business is growing and they have also recently acquired another one of our repackaging accounts. Let me know your thoughts.

Thanks  
Mike

----- Forwarded by Michael Cochrane/Anda/Anda/Andrx on 07/24/2009 11:10 AM -----

**Michael  
Cochrane/Anda/Anda/Andrx** To Al Paonessa III/Anda/Andrx  
07/14/2009 03:10 PM cc Patrick Cochrane/Anda/Andrx@Andrx, Norman  
Dodes/Anda/Anda/Andrx@Andrx, Seth  
Rudnick/Anda/Andrx@Andrx, Kim  
Bloom/Anda/Andrx@Andrx  
Subject Approval

Attached is usage information of the different Watson Hydrocodone products DRX used to buy from another wholesaler (Dik Drug). DSI which is another customer recently acquired DRX and we combined their limits because they are consolidating facilities. They are currently at 350,000 dosage units per month. I have filed their acquisition release, visited their facility in Santa Ana with Norman and their current mix is OK. Last month sales were almost \$400K. They have requested we increase their monthly limit to 500,000 and that is OK with me. Please approve.

Thanks  
Mike

----- Forwarded by Michael Cochrane/Anda/Anda/Andrx on 07/14/2009 03:02 PM -----

**Norman  
Dodes/Anda/Anda/Andrx** To Michael Cochrane/Anda/Anda/Andrx@Andrx



Confidential

Anda\_Opioids\_MDL\_0000077958

P-01616\_00001

07/14/2009 12:25 PM

cc

Subject: Fw: DSI CONTROLLED SUBSTANCE LIMITS

Mike,

Here is another usage report from DRX / Dispensing Solutions. Let's get together this afternoon to discuss, Bruce Mole wants us to call him later.

Thanks

Norman Dodes  
Director National Accounts  
Anda, Inc.  
Off: (800) 331-2632 ext- 4262  
Direct: (954) 217-4262  
Cell: (954)658-4970  
Fax: (877)399-6851  
email: Norman.Dodes@andanet.com

----- Forwarded by Norman Dodes/Anda/Anda/Andrx on 07/14/2009 12:24 PM -----

**Dan Welch**

<dwelch@drxdispensing.com>

To: "norman.dodes@andanet.com"

<norman.dodes@andanet.com>

07/14/2009 12:15 PM

cc: Bruce Mole <bmole@dispensingsolutionsinc.com>

Subject: DSI CONTROLLED SUBSTANCE LIMITS

Norman,

The attached documents are a snapshot of the purchase history of Watson Hydrocodone products acquired by the former DRx Pharmaceutical Consultants, Inc. (DRx) from 1/1/09 – 5/31/09. This purchase activity was exclusively conducted between DRx and DIK Drug Inc. As you can see between the 4 different strengths that our 5 month consumption was approximately 2.5MM tablets which translates into a monthly average of 500K tablets. Due to the recent merger of Dispensing Solutions Inc. (DSI) and DRx, I am requesting for a re-evaluation and increase to the monthly controlled substance limits through Anda that we allow us to stock a 90-day supply. Please contact myself or Bruce Mole if you have any questions concerning this matter.

Dan



**Dan Welch**  
**Materials Manager**  
**13795 W. Polo Trail Drive**  
**Lake Forest, Illinois 60045**  
**(D) 847.371.3365**  
**(F) 847.816.6063**  
**www.dispensingsolutionsinc.com**  
**www.dwelch@dispensingsolutionsinc.com**

---

This electronic transmission and any documents accompanying this electronic transmission contain confidential information belonging to the sender. This information may contain confidential health information that is legally privileged. The information is intended only for the use of the individual or entity named above. The authorized recipient of this transmission is prohibited from disclosing this information to any other party unless required to do so by law or regulation and is required to delete or destroy the information after its stated need has been fulfilled. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on or regarding the contents of this electronically transmitted information is strictly prohibited. If you have received this E-mail in error, please notify the sender and delete this message immediately.

[attachment "DRx Hydrocodone purchase history.pdf" deleted by Al Paonessa III/Anda/Andrx]